OptionalRegionHeading_Programs

Additional Presentations And Contributions

Coogan, C., Shaw, M., Rubenstein, M., McKiel, C.F. and Guinan, P.: Predicting response following cryotherapy for prostate cancer. 70th North Central Section of the American Urological Association, Tucson, Arizona, October 27-November 2, 1996.

DiDomenico, D., Brown, J., Shaw, M., Rubenstein, M. and Guinan, P.: AD-32 effective when administered intralesionally in a prostate cancer model. 2nd Clinical Congress, San Francisco, California, October 6-11, 1996.

Lievano, G., DiDomenico, D., Brown, J., Shaw, M., Rubenstein, M. and Guinan, P.: Predicting response in hormonal downsizing prior to radical prostatectomy. 2'nd Clinical Congress, San Francisco October 6-11, 1996.

Mirochnik, Y., Shaw, M., Slobodskoy, L., Glick, R., Lichtor, T., Rubenstein, M. and Guinan, P.: Establishment of the T98G glioblastoma tumor in athymic nude mice utilizing Matrigel and orthotopic implantation. Rush University Research Forum May 18-20, 1999, Abstract #89.

Mirochnik, Y., Guinan, P. and Rubenstein, M.: Delivery of antisense oligonucleotides to prostate cancer by monoclonal vehicles in in vivo and in vitro models. Rush University Research Forum May 18-20, 1999, Abstract #100.

Mirochnik, Y., Slobodskoy, L., Guinan, P., Uzoaru, I., Shott, S., Shaw, M. and Rubenstein, M.: Histologic, proliferative and karyotypic evaluation of 42 patients with stage IV prostate cancer. Rush University Research Forum Feb. 25-27, 1998, Abstract #111.

Mirochnik, Y., Slobodskoy, L., Guinan, P., Glick, R., Lichtor, T, and Rubenstein, M.: Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed towards mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor. Rush University Research Forum Feb. 25-27, 1998, Abstract #133.

Mirochnik, Y., Slobodskoy, L., Guinan, P., Uzoaru, I., Shott, S., Shaw, M. and Rubenstein, M.: Histologic proliferative and karyotypic evaluation of 42 patients with stage IV prostate cancer. RUSH Research Forum #111, Feb. 25-27, 1998.

Mirochnik, Y., Slobodskoy, L., Guinan, P., Glick, R., Lichtor, T. and Rubenstein, M.: Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed towards mRNA encoding transforming growth factor-a and the epidermal growth factor receptor. RUSH Research Forum #133, Feb. 25-27, 1998.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Optimizing the treatment of prostate cancer with antisense oligonucleotides through enhancement of cellular uptake (in vitro) and the utilization of specific delivery vehicles (in vivo). 5'th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association. Proceedings: Molecular Biology and New Therapeutic Strategies: Cancer Research in the 21'st Century. Maui, HI; Feb. 12-16, 2001.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Delivery of oligonucleotides to LNCaP prostate tumor cells utilizing antibody derived vehicles. Cancer, Cell Cycle and Therapeutics, Steamboat Springs, CO, January 8-13, 2000.

Rubenstein, M.: Delivered a talk on Prostate Cancer Research at the 21'st Annual Conference of the Cancer Federation, in Riverside, CA, May 2, 1999.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Delivery of antisense oligonucleotides to LNCaP prostate cancer cells utilizing two monoclonal antibody derived vehicles. IBC's 6'th Annual International Conference on Oligo-Therapeutics: Molecular Tools and Novel Therapeutic Strategies, La Jolla, CA, May 3-5, 1999.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed towards mRNA encoding transforming growth factor-a and the epidermal growth factor receptor. IBC's 5'th Annual International Conference on Antisense DNA & RNA Based Therapeutics, Coronado, CA, February 2-3, 1998.

Rubenstein, M., Glick, R., Mirochnik, Y. and Guinan, P.: Antisense oligonucleotide treatment of the T98G glioblastoma cells utilizing sequences directed against mRNA encoding transforming growth factor- and the epidermal growth factor receptor. The Fourth Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association on Innovative Approaches to the Prevention, Diagnosis, and Therapy of Cancer, Maui, HI, February 16-21, 1998.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Antisense oligonucleotide intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice. Cambridge Healthtech Institute conference on Antisense Technologies, San Francisco, CA, June 21-23, 1998.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Dose response and cellular uptake of antisense oligonucleotides to transforming growth factor-a and the epidermal growth factor receptor of the T98G glioblastoma. Cambridge Healthtech Institute Conference on Antisense Technologies, San Francisco, CA, June 21-23, 1998.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed towards mRNA encoding transforming growth factor-a and the epidermal growth factor receptor. IBC Conference on Antisense: DNA and RNA Based Therapeutics, Coronado, California, February 2-3, 1998.

Rubenstein, M., Glick, R., Mirochnik, Y. and Guinan, P.: Antisense oligonucleotide treatment of T98G glioblastoma cells utilizing sequences directed against mRNA encoding transforming growth factor-a and the epidermal growth factor receptor. Abstract C-35, Innovative Approaches to the Prevention, Diagnosis, and Therapy of Cancer, Maui, Hawaii, February 16-21, 1998.

Rubenstein, M., Mirochnik. Y. and Guinan, P.: Antisense oligonucleotide intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice. IBC Conference on Antisense Technologies, San Francisco, California, June 21-23, 1998.

Rubenstein, M., Mirochnik. Y. and Guinan, P.: Dose response and cellular uptake of antisense oligonucleotides to transforming growth factor-a and the epidermal growth factor receptor of the T98G glioblastoma. IBC Conference on Antisense Technologies, San Francisco, California, June 21-23, 1998.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: A method for the specific delivery of biotinylated antisense oligonucleotides to prostate cancer cells utilizing hybrid monoclonal antibodies. IBC Conference on Antisense Therapeutics. San Diego, CA; February 6-7, 1997.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Delivery of biotinylated agents to prostate cancer cells utilizing hybrid monoclonal antibodies. RUSH Research Forum #113, February 25-27, 1997.

Rubenstein, M., Sharifi, R., Ray, V., Lievano, G., Mirochnik, Y., Shaw, M. and Guinan, P.: Radical prostatectomy after androgen blockade: Are marker and morphologic changes significant? RUSH Research Forum #114, Feb. 25-27, 1997.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Proceedings; Basic and Clinical Aspects of Breast Cancer. Keystone, CO; March 7-12, 1997.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Growth factor deprivation therapy of hormone insensitive breast cancer utilizing antisense oligonucleotides. Abstract 425, Keystone Symposia on Breast and Prostate Cancer: Basic Mechanisms, Taos, New Mexico, January 29-February 4, 1996.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice utilizing antisense oligonucleotides. IBC Conference on Oligonucleotide and Gene Therapy based Antisense Therapeutics, Coronado, California, February 15-16, 1996.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: The specific delivery of biotinylated agents to prostate cancer cells utilizing hybrid monoclonal antibodies. IBC 2'nd International Conference on Advances in the Effective Delivery of Proteins, Peptides and Nucleic Acids, Coronado, California, December 12-13, 1996.

DiDomenico, D., Bridges, P., Sharifi, R., Rubenstein, M., Guinan, P.: Survival of Mexican-American males with seminoma. Rev. Invest. Clin. 49:93-96, 1997.

Guinan, P.:Hippocrates: Where are you when we need you? CMQ, J of the Guild of Catholic Doctors, Vol. L1, No.1, (291), 8-11, 2001.

Guinan, P.: Where has catholic medical ethic gone? CMQ, J of the Guild of Catholic Doctors, Vol. L1, No.4, (294), 5-8, 2001.

Rubenstein, M., Glick, R., Lichtor, T., Mirochnik, Y., Chou, P. and Guinan, P.: Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-a and the epidermal growth factor receptor. Med. Oncol. 18:121-130, 2001.

Rubenstein, M., Mirochnik, Y., Slobodskoy, L. and Guinan, P.: Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines. Methods. Find. Clin. Pharmacol. 23:487-490, 2001.

Shaw, M., Ratanawong, S., Chou, P., Ray, V., Mirochnik, Y., Slobodskoy, L., Rubenstein, M. and Guinan, P.: Paclitaxel, bropirimine and linomide: Effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms. Methods Find. Exp. Clin. Pharmacol. 20:111-114, 1998.

Uzoaru, I., Rubenstein, M., Mirochnik, Y., Slobodskoy, L., Shaw, M. and Guinan, P.: An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J. Surg. Oncol. 67:33-37, 1998.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Enhanced cellular uptake and use of specific delivery vehicles in treating prostate cancer with antisense oligonucleotides. Proceedings AACR 42:377a, 2001.

Rubenstein, M., Mirochnik, Y. and Guinan, P.: Optimizing the treatment of prostate cancer with antisense oligonucleotides through enhancement of cellular uptake (in vitro) and the utilization of specific delivery vehicles (in vivo). 5'th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association. Proceedings: Molecular Biology and New Therapeutic Strategies: Cancer Research in the 21'st Century. Maui, HI; Feb. 12-16, 2001.